Doctors long warned AFib patients to ditch coffee, but a major new trial proves daily caffeinated joe slashes recurrence risk by 39%.
Story Highlights
- DECAF Trial: Coffee drinkers post-cardioversion had 47% AFib recurrence vs. 64% for abstainers (HR 0.61, P=0.01).
- First randomized trial challenging caffeine myths; involved 200 habitual drinkers across US, Canada, Australia.
- Moderate intake (1+ cup/day for 6 months) linked to anti-inflammatory benefits, more activity, healthier swaps.
- Findings presented at AHA 2025, published in JAMA—poised to reshape clinician advice for millions.
DECAF Trial Details
Researchers enrolled 200 adults with persistent atrial fibrillation or atrial flutter history who drank about 7 cups weekly at baseline. All underwent electrical cardioversion to restore normal rhythm. Randomization split them into coffee (at least 1 caffeinated cup daily) or abstinence (no coffee or caffeine) for 182 days. The coffee group maintained a similar intake; abstainers dropped to zero. Follow-up ended June 5, 2025, across 5 hospitals in the US, Canada, Australia. Mean participant age was 69; 71% male.
Striking Results Challenge Old Advice
Coffee consumers saw 47% recurrence of AFib or atrial flutter over 6 months, compared to 64% in the abstinence group. Hazard ratio favored coffee at 0.61 (95% CI 0.42-0.89; P=0.01), indicating 39% lower risk. No prior randomized trials tested this directly; observational data hinted at benefits but lacked rigor. Trial led by Christopher X. Wong of UCSF and University of Adelaide, with senior author Gregory M. Marcus at UCSF. Open-label design focused on prior drinkers, excluding high-caffeine or non-drinkers.
Watch:
Why Coffee May Protect Hearts
Lead author Wong stated doctors traditionally urged minimizing coffee, but results suggest it is safe and protective for AFib patients post-cardioversion. Potential mechanisms include coffee’s anti-inflammatory compounds, blood pressure lowering, or boosting daily steps by about 1,000. Abstainers may have substituted less healthy drinks, worsening outcomes. Senior author Marcus noted no adverse events but called for studies on new drinkers and higher intakes. Consensus holds for moderate use in this group.
Got a health question? Ask our AI doctor instantly, it’s free.
Trial Limitations and Broader Reach
DECAF (NCT05121519) was first-of-its-kind but open-label, risking bias, and limited to baseline coffee drinkers averaging moderate amounts—not energy drinks or excess. AFib affects 59 million globally; recurrence post-cardioversion hits 50-60% typically. Short-term, findings ease restrictions for coffee-loving patients; long-term, they may update guidelines, cut unnecessary abstinence, and yield healthcare savings via fewer strokes or drugs. No industry funding influenced academic-led effort.
Implications for Everyday Americans
Under President Trump’s renewed focus on practical health wins—like ditching overreach in food dyes and empowering personal choices—this trial arms AFib patients against one-size-fits-all edicts from the old guard. Enjoy that cup without guilt; science backs common-sense habits over fearmongering. AHA presented results in November 2025 alongside JAMA publication, reaching 37,000 clinicians. Replication needed, but evidence tilts toward freedom in the coffee cup.
Your instant doctor companion – online 24 hours a day.
Sources:
Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation After Electrical Cardioversion (DECAF Trial)
UCSF: Coffee safe for A-Fib
mindbodygreen: One Cup of Coffee Daily Cuts AFib Recurrence Risk by 39%
ACC: DECAF AHA 2025
AHA Newsroom: Cup of coffee a day may not be harmful for some adults with AFib
